Yao K et al / Acta Pharmacol Sin 2003 Mar; 24 (3): 219-224
-adrenoceptor stimulation
on endothelial nitric-oxide synthase phosphorylation of human umbilical vein
endothelial cells1
YAO Kang, XU Biao2, LIU Ya-Ping, Albert FERRO3
Department of Cardiology, Affiliated Zhong Da Hospital of Southeast University, Nanjing 210009, China; 3Department of Clinical Pharmacology, St Thomas' Hospital, King's College, London, England
1 Project supported by Wellcome Trust International Research Development Awards (Grant No 055678/Z/98/Z).
2 Correspondence to Prof XU Biao, MD. Phn 86-25-327-2018. Fax 86-25-327-2010. E-mail yaokangd@hotmail.com
Received 2002-04-01 Accepted 2002-12-13
KEY WORDS umbilical veins; beta-adrenergic receptors; nitric-oxide synthase; vascular endothelium; isoproterenol; Western blotting
ABSTRACT
AIM: To investigate the effects of isoprenaline on the phosphorylation
level of endothelial nitric oxide synthase (eNOS) of human umbilical vein endothelial
cells (HUVEC) and to elucidate the regulation mechanisms of
-adrenoceptor
(
-AR) on eNOS activity. METHODS:
HUVEC were exposed to isoprenaline (1
mol/L)
for 30 min, in the absence or presence of selective
1-
or
2 -adrenoceptor antagonists.
eNOS was then isolated by immunoprecipitation using a specific eNOS antibody.
eNOS activity was determined by the conversion of L-[3H]arginine
to L- [3H]citrulline. The levels of eNOS expression and eNOS
phosphorylation were measured by Western blotting. RESULTS: Treatment
of HUVEC with isoprenaline (1
mol/L)
for 30 min caused no measureable change in eNOS expression. However, eNOS activity
and serine phosphorylation level were significantly increased (P<0.01).
This effect could be abolished by a selective
2-adrenoceptor
antagonist ICI 118551. CONCLUSION: Isoprenaline increases eNOS activity
of HUVEC, this is mediated by
2-adrenoceptor
and associated with an increase of eNOS serine phosphorylation level.
INTRODUCTION
Stimulation of
-adrenoceptors
(
-AR) on vascular smooth muscle
results in vasorelaxation through activation of andenylyl cyclase and consequent
increase in tracellular cyclic adenosine-monophosphate (cAMP). Vascular endothelial
cells also may express
-adreno-ceptors,
and there is increasing evidence that these may contribute to
-adrenergic
vasorelaxation because vascular relaxation to
-AR
stimulation is impaired by removal of the endothelium or by inhibition of endothelial
nitric oxide synthase (eNOS)[1,2]. But the signal transduction
mechanism involved is unclear. We have recently demonstrated in cultured human
umbilical vein endothelial cells (HUVEC) and in rabbit femoral artery in
vivo that stimulation of
-AR
with isoprenaline increased NO production. cAMP generation (mediated either
by
-AR stimulation or by other
pathway) can give rise to activation of eNOS[3,4]. Agonists such
as acetylcholine or histamine cause an influx of excellular Ca2+
which, by promoting the binding of calmodulin to NOS, leads to activation[5].
However, we have found that isoprenaline increases adenylyl cyclase activity
and intracellular cAMP in HUVEC, but that this is not associated with an increase
in tracellular [Ca2+] as assessed by Furo-2 fluorescence[3].
Indeed, recent evidence suggests that eNOS can also be activated in a calcium-independent
manner by fluid shear stress[6] and estrogen[7], and that
phosphorylation of eNOS is possiblely crucial for this novel calcium-independent
activation. In the present study , we try to investigate the effect of isoprenaline
on the activity of eNOS in HUVEC, and to examine whether phosphorylation of
eNOS is involved in the process.
MATERIALS AND METHODS
Isolation and culture of HUVEC Fresh umbilical cords were obtained following delivery of healthy babies to healthy normotensive mothers. Approval was granted by the affiliated hospital of Southeast University. Human umbilical vein endothelial cells were obtained[9]. The cells were cultured in medium 199 (Gibco, USA), supplemented with 20 % fetal bovine serum and endothelial cell growth supplement 120 mg/L (Sigma,USA), into a 25-mL gelatin-coated culture flask, at 37 ºC in 5 % CO2+95 % air. At confluence, cells were detached from the substratum by brief exposure to trypsin-edetic acid (at 37 ºC for 2 min ), pelled (400×g, 5 min), and passed at a split ratio of 1:3. Confluent cells at passage 2 were used for all experiments.
Immunoprecipitation of eNOS Cells were washed twice with warm
PBS and treated with isoprenaline or vehicle for 30 min, in the absence or presence
of
1-AR or
2-AR
antagonist. At the end of the incubation, the cells were washed twice with ice-cold
PBS, and lysed on ice for 30 min in 0.5 mL of lysis buffer (Tris-HCl 25 mmol/L,
edetic acid 1 mmol/L, NaCl 150 mmol/L, NaF 50 mmol/L, 1 % Triton-100, PMSF 1
mmol/L, leupeptin 1 mg/L, aprotinin 1
mol/L,
pH 7.6). Lysates were transferred to an eppendorf tube and rotated at 15000×g,
4 ºC for 15 min. The supernatant containing equal amounts of protein were
added to Protein A-Sepharose CL4B beads (Amersham, UK) precoated with anti-eNOS
antibody (Santa Cruz,Germany), at 4 ºC for 2 h. Having been extensively
washed with PBS, the beads were divided into two equal aliquots: one was used
for NOS activity measurements, and the other for Western blotting studies.
Western blotting of immunoprecipitated eNOS Immunoprecipitates were boiled in SDS-PAGE sample buffer (glycerol 8 %, SDS 1.6 %, 2-mercapatoethanol 64 mmol/L, Tris-HCl 0.5 mol/L, pH 6.8) for 5 min, and separated by SDS-PAGE on an 8 % gel, followed by electroblotting for 1 h onto a nitrocelluose membrane (Amersham, UK). Membranes were blocked by a 2-h incubation at 4 ºC in TBST (Tris-HCl 20 mmol/L pH 7.6, NaCl 137 mmol/L, 0.1 % Tween-20) containing 5 % blocking agents (Amersham USA), followed by a 1-h incubation in rabbit anti-eNOS antiserum (Santa Cruz ,Germany) at dilution 1:1000. Having been extensively washed in TBST, membranes were incubated for 1 h with goat anti-rabbit horseradish peroxidase-conjugated secondary antibody at room temperature. They were then extensively washed in TBST, and developed using enhanced chemiluminescene substrate (ECL, Amersham UK). Bands thus revealed were analyzed by scanning densitometry.
Analysis of serine phosphorylation To assay for serine phosphorylation of eNOS, nitrocellucose membranes were stripped by incubation in stripping buffer(Tris-HCl 62.5 mmol/L, pH 6.9, 2 % SDS, 2-merca-patoethanol 100 mmol/L) at 50 ºC for 30 min. Stripped membranes were reprobed with anti-phosphoserine antibody (Santa Cruz,Germany) as before.
Activity of immunoprecipatated eNOS eNOS immunoprecipitated and immobilized
on protein A-Sepharose CL4B beads was resuspended in 100
L
of NOS assay buffer of the following composition: Tris-HCl 50 mmol/L, edetic
acid 0.1 mmol/L, egtazic acid 0.1 mmol/L, NaF 10
mol/L,
leupeptin 2
mol/L, aprotinin 1
mol/L,
PMSF 1 mmol/L, NADPH 1 mmol/L, tetrahydrobiopterin 3
mol/L,
calmodulin 100 nmol/L, CaCl2 2.5 mmol/L, L-arginine 10
mol/L,
pH 7.5. L-[3H]arginine (Sigma,USA) 7400 Bq was added and,
following incubation at 37 ºC for 30 min, the reaction was quenched by
the addition of 1 mL of ice-cold stop buffer (HEPES 20 mmol/L, edetic acid 2
mmol/L, egtazic acid 2 mmol/L, pH 5.5). An excess of Dowex resin(Sigma, USA)
was added, this was mixed thoroughly and allowed to settle for 10 min. The resultant
supernatant, containing the L-citrulline fraction, was counted by liquid
scintillation.
Statistical analysis The data were expressed as mean±SD and statistically analyzed using one-way ANOVA. Values considered to be statistically significant were P<0.05.
RESULTS
Effect of isoprenaline on eNOS activity in HUVEC eNOS activity was evaluated
from the conversion of L-[3H]arginine to L-[3H]citrulline
production. Isoprenaline increased L-[3H]citrulline production
by 34.4 % as compared with basal (P<0.01). To determine whether the
-AR mediated increase in L-[3H]
citrulline production was mediated through
1
or
2-AR, we performed
a large series of experiments with CGP 20712A 300 nmol/L (a
1-AR
selective antagonist) or ICI 118551 100 nmol/L (a
2-AR
selective antagonist). Coincubation with CGP 20712A did not affect L-[3H]citrulline
production in response to isoprenaline. By contrast, in the presence of ICI
118551, isoprenaline did not increase L-[3H]citrulline formation
suggesting that the activation of eNOS by isoprenaline was mediated exclusively
through
2-AR (Fig 1).
Fig 1. Effects of isoprenaline (ISO) on eNOS acvitity in HUVEC. Cells were
incubated for 30 min with ISO (1
mol/L),
in the absence or presence of selective
1-
or
2-adrenoceptor antagonists.
eNOS was then immunoprecipitated from lysed cells. L-[3H]arginine
to L-[3H]citrulline conversion was determined in the immunprecipitate.
Results are expressed by percent change in L-[3H]citrulline
formation in response to different treatments compared with control cells (100
%). n=4. cP<0.01 vs control. fP<0.01
vs ISO.
Effect of isoprenaline on serine phosphorylation of eNOS in HUVEC
To investigate whether the observed effects of isoprenaline on eNOS activity
in HUVEC were caused by phosphorylative modification of the eNOS enzyme itself,
rather than changing expression of eNOS, HUVEC were exposed to isoprena line
or vehile for 30 min. eNOS was then isolated from lysed HUVEC by immunoprecipitate
using a specific antiserum to eNOS, and the resulting immunoprecipitate was
divided into two equal aliquots: one was used for NOS activity measurements,and
the other for Western blotting studies. Western blotting, using the same eNOS
antiserum, revealed the presence of a band at 135 kDa, corresponding to the
known molecular mass of human eNOS (Fig 2A, up panel). Scanning densitometric
analysis revealed no change in the amount of eNOS present, following treatment
with isoprenaline (1
mol/L), in the
absence or presence of
1
or
2-AR selective antagonist
(Fig 2B, up panel). Following stripping of the membrane and reprobing with a
specific rabbit antiserum to phosphoserine groups, a band was found once again
at 135 kDa (Fig 2A, botom panel). Scanning densitometry demonstrated increased
band density in response to isoprenaline, which was prevented by ICI 118551
100 nmol/L (Fig 2B, botom panel).
Fig 2. Effect of isoprenaline (ISO) on serine phosphorylation of eNOS in
HUVEC. Cells were incubated for 30 min with isoprenaline 1
mol/L,
in the absence or presence of selective
1-
or
2-adrenoceptor antagonists.
eNOS was isolated by immunoprecipitation. A, Western blot of its phosphoserine
content following different treaments. B, Serine phosphorylation of eNOS, quantified
by scanning densitometry of bands following Western blotting and probing using
anti-eNOS (top panel) and anti-phosphoserine(bottom panel) antibodies. n=4.
bP<0.05, cP<0.01 vs
control (CON). fP<0.01 vs ISO.
DISCUSSION
Previous in vitro and in vivo studies have suggested that
-andrenoceptor-mediated
vasorelaxation may have an endothelium-dependant compoment in several animal
species. Dawes et al[10] showed that infusion of isoprenaline
into the brachiartery of human subjects induced an increase in forearm blood
flow, and that the response was inhibited by coinfusion of the NOS inhibitor
L-NMMA. We previously demonstrated in cultured HUVEC in vitro
and in rabbit femoral artery in vivo, that
-adrenoceptor
activation or cyclic AMP elevation by other means stimulated NO production.
The present study showed that treatment of HUVEC with isoprenaline significantly
increased serine phosphorylation level and eNOS activity, this effect could
be abolished by a selective
2-adrenoceptor
antagonist ICI 118551.
Vasodilative substances such as acetylcholine, bradykinin have been shown previously
to exert their action via an endothelium-dependent manner and NO production.
Sympathoadrenal system and vascular endothelium L-arginine/NO system
are both very important to cardiovascular homeostasis. But interactions between
the two systems are known little. Here, we found that stimulation of
-adrenoceptor
in HUVEC with isoprenaline elicited an increase in conversion of L-arginine
to L-citrulline, indicating an increase in NOS activity. This effect
was attributable to
2-adrenoceptor
subtype, because ICI 118551 completely blocked the increase of eNOS activity
caused by isoprenaline. The physiological consequences of vascular endothelial
NO production in response to b-adrenergic activation are present unknown, but
it is possible that this process is important in the normal control of vessel
tone by the sympatheadrenal system. Furthermore, certain disease states, including
atheresclerosis, heart failure and essential hypertension are associated with
both endothelial dysfunction and impaired
-adrenergic
vasodilation[11,12]. The present findings suggest that these abnormalities
may be causally related.
The eNOS is classified as a constitutive and strictly Ca2+/calmodulin-dependent
enzyme[13]. Agonists which have been shown previously to promote
NO release from endothelium, including histamine and acetylcholine, cause an
influx of extracellular Ca2+ by promoting the binding of calmodulin
to the endothelial constitutive isoform of eNOS, leading to activation. Indeed,
we have confirmed that histamine caused a transient rise in Ca2+ in
HUVEC. However, isoprenaline was without demonstrable effect on Ca2+
as assessed by Furo-2 fluorescence, suggesting that activation of eNOS by
-adrenoceptor
stimulation probably occurs by a novel mechanism not involving Ca2+
influx and calmodulin activation. It is unlikely to be due to activation of
the inducible (Ca2+-independent) isoform of NOS, since cultured HUVEC
have previously been found to express the endothelial isoform only, even following
stimulation with proinflammatory cytokines[14]. Protein phosphorylation
plays a central role in signal transduction pathways regulating a variety of
biological processes, including the activities, biosynthesis and degradation
of many enzymes. Possible mechanisms of the stimulative effect of isoprenaline
on endothelial NOS activation include either increase in eNOS expression or
a change in post-translational modification perhaps through phosphorylation.
To investigate the possibility that isoprenaline exerts an effect on the enzyme
itself, we isolated eNOS from HUVEC by immunoprecipita-tion, following 30-min
exposure of HUVEC to isoprenaline or vehile. we quantified the eNOS thus isolated
by Western blotting and scanning densitometry. Treatment of HUVEC with isoprenaline
(1
mol/L) for 30 min caused no measureable
change in eNOS expression. However, eNOS activity and serine phosphorylation
level were significantly increased (P<0.01). This effect could be
abolished by a selective
2-adrenoceptor
antagonist ICI 118551. It seems likely that the stimulation in eNOS activity
in response to isoprenaline was caused by increasing phosphylation of serine
residues in the eNOS enzyme. Indeed, recent evidence suggests that eNOS can
also be activated in a calcium-independent manner by fluid shear stress and
VEGF, presumable through phosphorylation on serine1179 mediated by Akt (protein
kinase B)[15,16], thus enhancing the sensitity of the enzyme to calcium-activated
calmodulin[17]. Further studies are required to elucidate the definite
kinase and mechanisms of
-adrenoceptor-cyclic
AMP-mediated activation of eNOS in these cells.
From our result of Western blotting, you can see another band at 90 kDa position. We supposed that it was heat shock protein 90 (Hsp90). Indeed, Hsp90 has recently been identified as an eNOS-associated protein, and its binding to the enzyme increases catalytic activity[18,19]. A certain amount of Hsp90 appears to complex with eNOS in unstimulated endothelial cells as immunoprecipitation of Hsp90 results in the recovery of eNOS, and vice versa. In all cases the association of Hsp90 with eNOS increased NO production and was prevented by pretreatment with geldanamycin (a specific inhibitor of Hsp90). Further work is needed to elucidate the possible interaction between these two proteins.
In conclusion, isoprenaline significantly increased eNOS activity in cultured
HUVEC associated with an increase in serine phosphorylation. Furthermore, all
the measured responses to isoprena-lined were mediated exclusively throuth
2-AR
subtype activation. These finds clarify the mechanism of
2-adrenoceptor
action on human blood vessel cells and may be of physiological and pathophysiological
importance if they are representative of other vascular beds.
ACKNOWLEDGEMENT We thank Dr HAO Feng and SONG Ping for their assistance in the expriment.
REFERENCES
2-adrenoceptors
in human umbilical vein. Br J Pharmacol 1999; 126: 1872-80.
2-adrenergic
stimulation or cyclic AMP elevation in vivo. Br J Pharmacol 2000;129:
969-74.
-
estradiol regulation of human endothelial cell based nitric oxide release,
independent of cytosolic Ca2+ mobiliza-tion. Circ Res 1997; 81:
885-92.
-adrenergic
agonists in human forearm. Circulation 1997; 95: 2293-98.